Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Drug Resistance Patterns in Hiv Patients With Virologic Failure in Iran Publisher



Alinaghi SAS1 ; Rasoolinejad M1 ; Najafi Z1 ; Dadras O2 ; Malekianzadeh E3 ; Mirzazadeh A4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Global Health and Socioepidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  3. 3. Dezful University of Medical Sciences, Dezful, Iran
  4. 4. HIV/STI Surveillance Research Center, WHO Collaborating Center for HIV Surveillance, Kerman University of Medical Sciences, Kerman, Iran
  5. 5. Department of Epidemiology and Biostatistics, Institute for Global Health Sciences, University of California San Francisco, CA, United States

Source: Archives of Clinical Infectious Diseases Published:2019


Abstract

We reviewed the medical charts of 1,700 patients diagnosed with HIV who referred to a central HIV clinic in Tehran between 2004 and 2017. Participants who had a viral load of > 200 copies/mL after six months or more on antiretroviral therapy (ART) were grouped as virologic failure (VF). We assessed the demographic characteristics, diagnosis date, first ART regimen, and resistance to various ART drugs. Out of 1,700 patients, 72 (4.2%) had a treatment failure. Among those with treatment failure, 51.3% were on zidovudine + lamivudine + efavirenz, 13.9% were on tenofovir + lamivudine + lopinavir/ritonavir, and 12.5% were on tenofovir + emtricitabine + efavirenz. In patients with treatment failure, the highest resistance was to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) combination (44.4%). In these patients, resistance to tenofovir (one of the NRTIs) was 29.1%. The highest treatment failure was observed among patients treated with nevirapine (NVP) and efavirenz (EFV)-based regimen. Our findings suggest that protease inhibitors should be considered as first-line drugs in ART regimens in VF patients in Iran. © 2019, Archives of Clinical Infectious Diseases.
Related Docs
1. Evaluation of Acquired Hiv Drug Resistance Among People Living With Hiv Who Have Taken Antiretroviral Therapy for 9-15 Months in 14 Triangular Clinics in Iran, 2015-2016, Intervirology (2019)
2. Epidemiology of Hiv in Iran, Current HIV Research (2020)
3. Hiv Drug Resistance and Phylogeny Profile in Naive and Antiretroviral-Experienced Patients in Tehran, Iran, Intervirology (2017)
4. Antiretroviral Drug Resistance Mutations in Naive and Experienced Patients in Shiraz, Iran, 2014, Archives of Virology (2016)
5. Hiv in Iran: Onset, Responses, and Future Directions, AIDS (2021)
6. Predictive Factors for Positive Hiv Test Results in a Hospital Setting, Archives of Clinical Infectious Diseases (2021)
7. Antiretroviral Drug Resistance Mutations Among Hiv Treatment Failure Patients in Tehran, Iran, Iranian Journal of Public Health (2017)
8. Gaps and Solutions of Hiv Testing, Care, and Treatment in Iran During 2018-2019, HIV and AIDS Review (2021)
Experts (# of related papers)
View all Related Experts
Seyed Ahmad Seyed Alinaghi (4)
Ladan Abbasian (1)